Sanofi SA

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

27 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q3 2024 Aide mémoire

26 Sep 2024 01:30:00 By Nasdaq GlobeNewswire

Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

20 Sep 2024 18:36:29 By Nasdaq GlobeNewswire

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

20 Sep 2024 07:45:00 By Nasdaq GlobeNewswire

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study

20 Sep 2024 05:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - August 2024

16 Sep 2024 12:44:49 By Nasdaq GlobeNewswire

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

12 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

11 Sep 2024 01:05:00 By Nasdaq GlobeNewswire

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

11 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis

02 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - July 2024

09 Aug 2024 15:11:38 By Nasdaq GlobeNewswire

Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant

08 Aug 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Online availability of Sanofi’s half-year financial report for 2024

25 Jul 2024 10:56:55 By Nasdaq GlobeNewswire

Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded

25 Jul 2024 01:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares – June 2024

22 Jul 2024 16:05:35 By Nasdaq GlobeNewswire

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

17 Jul 2024 17:27:35 By Nasdaq GlobeNewswire

Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

03 Jul 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

26 Jun 2024 17:30:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q2 2024 Aide-mémoire

25 Jun 2024 13:32:52 By Nasdaq GlobeNewswire

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

21 Jun 2024 03:30:00 By Nasdaq GlobeNewswire